File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.11622/smedj.2021164
- PMID: 34688228
- Find via
Supplementary
-
Citations:
- PubMed Central: 0
- Appears in Collections:
Article: Treatment and outcomes of high-risk neuroblastoma in Southeast Asia: a single institution experience and review of the literature
Title | Treatment and outcomes of high-risk neuroblastoma in Southeast Asia: a single institution experience and review of the literature |
---|---|
Authors | |
Keywords | chemotherapy child haematopoietic stem cell transplantation neuroblastoma |
Issue Date | 2021 |
Publisher | Singapore Medical Association. The Journal's web site is located at http://www.sma.org.sg/smj/smjcurrent.html |
Citation | Singapore Medical Journal, 2021, Epub 2021-10-24 How to Cite? |
Abstract | Introduction: In Europe and Northern America, the majority of children with high-risk neuroblastoma survive the disease. Elsewhere, treatment outcomes are poor.
Methods: A retrospective review of children treated for high-risk neuroblastoma in a single institution in Singapore from 2007 to 2019 was carried out. Treatment consisted of intensive chemotherapy, surgery aimed for gross total resection of residual disease after chemotherapy, consolidation with high-dose therapy followed by autologous stem cell rescue, radiotherapy to the primary and metastatic sites, followed by maintenance treatment with either cis-retinoic acid or anti-disialoganglioside (anti-GD2) monoclonoal antibody therapy. Survival data were examined on certain clinical and laboratory factors.
Results: There were 57 children with 32 males treated for high-risk neuroblastoma. Their mean age was 3.9 (0.7–14.9) years. The median follow-up time was 5.5 (1.8–13.0) years for the surviving patients. There were 31 survivors with 27 surviving in first remission, and 5-year overall survival and event-free survival rates were 52.5% and 47.4%, respectively. On log-rank testing, only the group of 17 patients who were exclusively treated at our centre had a survival advantage. Their 5-year overall survival rate, compared with others whose initial chemotherapy was done elsewhere, was 81.6% versus 41.1% (p = 0.011), and that of event-free survival was 69.7% versus 36.1% (p = 0.032). Published treatment results were found from four countries in Southeast Asia with 5-year overall survival rates from 13.5%–28.2%.
Conclusion: Intensified medical and surgical treatment for high-risk neuroblastoma proved to be effective with superior survival rates compared with previous data from Southeast Asia. |
Persistent Identifier | http://hdl.handle.net/10722/307698 |
ISSN | 2023 Impact Factor: 1.7 2023 SCImago Journal Rankings: 0.374 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, ACW | - |
dc.contributor.author | Chui, CH | - |
dc.contributor.author | Kwok, R | - |
dc.contributor.author | Lee, KS | - |
dc.contributor.author | Fong, CM | - |
dc.contributor.author | Wong, WHS | - |
dc.date.accessioned | 2021-11-12T13:36:30Z | - |
dc.date.available | 2021-11-12T13:36:30Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | Singapore Medical Journal, 2021, Epub 2021-10-24 | - |
dc.identifier.issn | 0037-5675 | - |
dc.identifier.uri | http://hdl.handle.net/10722/307698 | - |
dc.description.abstract | Introduction: In Europe and Northern America, the majority of children with high-risk neuroblastoma survive the disease. Elsewhere, treatment outcomes are poor. Methods: A retrospective review of children treated for high-risk neuroblastoma in a single institution in Singapore from 2007 to 2019 was carried out. Treatment consisted of intensive chemotherapy, surgery aimed for gross total resection of residual disease after chemotherapy, consolidation with high-dose therapy followed by autologous stem cell rescue, radiotherapy to the primary and metastatic sites, followed by maintenance treatment with either cis-retinoic acid or anti-disialoganglioside (anti-GD2) monoclonoal antibody therapy. Survival data were examined on certain clinical and laboratory factors. Results: There were 57 children with 32 males treated for high-risk neuroblastoma. Their mean age was 3.9 (0.7–14.9) years. The median follow-up time was 5.5 (1.8–13.0) years for the surviving patients. There were 31 survivors with 27 surviving in first remission, and 5-year overall survival and event-free survival rates were 52.5% and 47.4%, respectively. On log-rank testing, only the group of 17 patients who were exclusively treated at our centre had a survival advantage. Their 5-year overall survival rate, compared with others whose initial chemotherapy was done elsewhere, was 81.6% versus 41.1% (p = 0.011), and that of event-free survival was 69.7% versus 36.1% (p = 0.032). Published treatment results were found from four countries in Southeast Asia with 5-year overall survival rates from 13.5%–28.2%. Conclusion: Intensified medical and surgical treatment for high-risk neuroblastoma proved to be effective with superior survival rates compared with previous data from Southeast Asia. | - |
dc.language | eng | - |
dc.publisher | Singapore Medical Association. The Journal's web site is located at http://www.sma.org.sg/smj/smjcurrent.html | - |
dc.relation.ispartof | Singapore Medical Journal | - |
dc.subject | chemotherapy | - |
dc.subject | child | - |
dc.subject | haematopoietic stem cell transplantation | - |
dc.subject | neuroblastoma | - |
dc.title | Treatment and outcomes of high-risk neuroblastoma in Southeast Asia: a single institution experience and review of the literature | - |
dc.type | Article | - |
dc.identifier.email | Wong, WHS: whswong@hku.hk | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.11622/smedj.2021164 | - |
dc.identifier.pmid | 34688228 | - |
dc.identifier.hkuros | 330192 | - |
dc.identifier.volume | Epub 2021-10-24 | - |
dc.publisher.place | Singapore | - |